ACADIA PHARMACEUTICALS INC cotiza a 19.78 USD y tiene una capitalización bursátil de $3.4B. En los últimos 12 meses ha facturado $1.1B con un margen de flujo de caja libre del 9.8%. Cotiza a 23.4 veces su flujo de caja libre (P/FCF) y a un PER de 9.0. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for neurological and rare disease in North America. The company offers NUPLAZID (pimavanserin), a selective serotonin inverse agonist/antagonist for the treatment of hallucinations and delusions assoc…
| Periodo | 2026-11 | 2026-08 | 2026-05 | 2026-02 |
|---|---|---|---|---|
| Real | — | $0.18 | $0.02 | $0.14 |
| Estimado | $0.18 | $0.04 | $0.08 | $0.14 |
| Sorpresa | — | +350.0% | -75.0% | +0.0% |
| Métrica | ACAD | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | 91.7% | 57.0% | +34.6% |
| Operating Margin | 9.8% | -38.6% | +48.4% |
| Net Margin | 36.5% | -33.6% | +70.1% |
| FCF Margin | 9.8% | -13.9% | +23.7% |
| ROE | 31.9% | -40.4% | +72.3% |
| ROA | 25.0% | -32.0% | +57.0% |
| Current Ratio | 3.83 | 2.84 | +0.99 |
| Debt / Equity | — | 0.28 | — |